Onco Wiki / drapeau rouge

Infection chronique par Helicobacter pylori (test positif de l'urée respiratoire, antigène s...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-CHRONIC-H-PYLORI-MALIGNANCY-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesDIS-GASTRIC
SourcesSRC-NCCN-BCELL-2025

Origine du drapeau rouge

DéfinitionChronic Helicobacter pylori infection (positive urea breath test, stool antigen, gastric biopsy histology, or stool PCR) in an individual without a current gastric malignancy diagnosis. IARC Group 1 carcinogen (H. pylori) — established etiological driver of gastric adenocarcinoma (intestinal-type primarily) and gastric MALT lymphoma. Eradication therapy reduces gastric-cancer incidence (NNT ~15 in high-incidence populations per Cochrane meta-analyses) and is curative for early-stage gastric MALT lymphoma in ~70-80% of cases (Wotherspoon regression). Prevention-persona RedFlag (§20 ratification 2026-05-18).
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "h_pylori_status",
      "value": "positive"
    },
    {
      "finding": "urea_breath_test",
      "value": "positive"
    },
    {
      "finding": "h_pylori_stool_antigen",
      "value": "positive"
    },
    {
      "finding": "h_pylori_biopsy_histology",
      "value": "positive"
    }
  ],
  "type": "lab_value"
}

Notes

Prevention-persona RedFlag (CHARTER §3 amended 2026-05-18 Path A, HCP-mediated). Fires when patient profile shows chronic H. pylori (positive UBT / stool antigen / biopsy histology / stool PCR) AND no confirmed gastric malignancy. Engine routes such patients to a PreventionPlan recommending eradication therapy (per IND-H-PYLORI-PREVENTION-ERADICATION) as the etiological-cancer- prevention pathway. Evidence for H. pylori → gastric cancer causation (IARC Group 1): multiple Cochrane meta-analyses show eradication reduces gastric adenocarcinoma incidence (RR ~0.54-0.66, NNT ~15-50 depending on population baseline incidence). Effect is stronger in high-incidence populations and in younger individuals where atrophic gastritis / intestinal metaplasia has not yet developed. Evidence for H. pylori → gastric MALT lymphoma: eradication is the first-line treatment for early-stage gastric MALT lymphoma, with Wotherspoon regression in ~70-80% of cases (especially t(11;18)- negative). This is treatment-persona territory (existing MALT lymphoma in setting of confirmed H. pylori → treatment Indication, not yet authored) — distinct from prevention persona (chronic H. pylori → prevent MALT/adenocarc...

Utilisé par

Indication